Evaluation of a Novel Prefilled Syringe Concept for Ophthalmic Applications: A Formative Human Factors Study

References

1. 1.↵
   1. Freund K. B.,
   2. Haller J. A.,
   3. Jumper J. M.,
   4. Liebmann J. M.,
   5. McCannel C. A.,
   6. Mieler W. F.,
   7. Ta C. N.,
   8. Williams G. A.

   1. Avery R. L.,
   2. Bakri S. J.,
   3. Blumenkranz M. S.,
   4. Brucker A. J.,
   5. Cunningham E. T.,
   6. D'Amico D. J.,
   7. Dugel P. U.,
   8. Flynn H. W.

   Jr; Freund K. B., Haller J. A., Jumper J. M., Liebmann J. M., McCannel C. A., Mieler W. F., Ta C. N., Williams G. A. Intravitreal Injection Technique and Monitoring: Updated Guidelines of an Expert Panel. Retina 2014, 34 (Supplement 12), S1–S18.

   OpenUrl
2. 2.↵
   1. Grzybowski A.,
   2. Told R.,
   3. Sacu S.,
   4. Bandello F.,
   5. Moisseiev E.,
   6. Loewenstein A.,
   7. Schmidt-Erfurth U

   , on behalf of the Euretina Board. 2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations. Ophthalmologica 2018, 239 (4), 181–193.

   OpenUrlPubMed
3. 3.↵
   1. Hartman R. R.,
   2. Kompella U. B.

   Intravitreal, Subretinal, and Suprachoroidal Injections: Evolution of Microneedles for Drug Delivery. J. Ocul. Pharmacol. Ther. 2018, 34 (1-2), 141–153.

   OpenUrl
4. 4.↵
   1. Shikari H.,
   2. Samant P.

   Intravitreal Injections: A Review of Pharmacological Agents and Techniques. J. Clin. Ophthalmol. Res. 2016, 4 (1), 51–59.

   OpenUrl
5. 5.↵
   1. Stewart M. W.

   The Expanding Role of Vascular Endothelial Growth Factor Inhibitors in Ophthalmology. Mayo Clin. Proc. 2012, 87 (1), 77–88.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   1. Mathalone N.,
   2. Arodi-Golan A.,
   3. Sar S.,
   4. Wolfson Y.,
   5. Shalem M.,
   6. Lavi I.,
   7. Geyer O.

   Sustained Elevation of Intraocular Pressure after Intravitreal Injections of Bevacizumab in Eyes with Neovascular Age-Related Macular Degeneration. Graefe’s. Arch. Clin. Exp. Ophthalmol. 2012, 250 (10), 1435–1440.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Ghasemi Falavarjani K.,
   2. Nguyen Q. D.

   Adverse Events and Complications Associated with Intravitreal Injection of anti-VEGF Agents: A Review of Literature. Eye 2013, 27 (7), 787–794.

   OpenUrlCrossRefPubMedWeb of Science
8. 8.↵
   1. Baudin F.,
   2. Benzenine E.,
   3. Mariet A.-S.,
   4. Bron A. M.,
   5. Daien V.,
   6. Korobelnik J. F.,
   7. Quantin C.,
   8. Creuzot-Garcher C.

   Association of Acute Endophthalmitis with Intravitreal Injections of Corticosteroids or anti–Vascular Growth Factor Agents in a Nationwide Study in France. JAMA Ophthalmol. 2018, 136 (12), 1352–1358.

   OpenUrl
9. 9.↵
   1. VanderBeek B. L.,
   2. Bonaffini S. G.,
   3. Ma L.

   Association of Compounded Bevacizumab with Postinjection Endophthalmitis. JAMA Ophthalmol. 2015, 133 (10), 1159–1164.

   OpenUrl
10. 10.↵
    1. Sheyman A. T.,
    2. Cohen B. Z.,
    3. Friedman A. H.,
    4. Ackert J. M.

    An Outbreak of Fungal Endophthalmitis after Intravitreal Injection of Compounded Combined Bevacizumab and Triamcinolone. JAMA Ophthalmol. 2013, 131 (7), 864–869.

    OpenUrl
11. 11.↵
    1. Edison L. S.,
    2. Dishman H. O.,
    3. Tobin-D’Angelo M. J.,
    4. Allen C. R.,
    5. Guh A. Y.,
    6. Drenzek C. L.

    Endophthalmitis Outbreak Associated with Repackaged Bevacizumab. Emerging Infect. Dis. 2015, 21 (1), 171–173.

    OpenUrl
12. 12.↵
    1. Goldberg R. A.,
    2. Shah C. P.,
    3. Wiegand T. W.,
    4. Heier J. S.

    Noninfectious Inflammation after Intravitreal Injection of Aflibercept: Clinical Characteristics and Visual Outcomes. Am. J. Ophthalmol. 2014, 158 (4), 733–737.e1.

    OpenUrl
13. 13.↵
    1. Freund K. B.,
    2. Laud K.,
    3. Eandi C. M.,
    4. Spaide R. F.

    Silicone Oil Droplets following Intravitreal Injection. Retina 2006, 26 (6), 701–703.

    OpenUrlCrossRefPubMedWeb of Science
14. 14.↵
    1. Avery R. L.,
    2. Castellarin A. A.,
    3. Dhoot D. S.,
    4. Pieramici D. J.,
    5. Nasir M. A.,
    6. Steinle N. C.,
    7. Avery L. P.,
    8. Gordon G. M.

    Large Silicone Droplets after Intravitreal Bevacizumab (Avastin). Retin. Cases Brief Rep. 2019, 13 (2), 130–134.

    OpenUrl
15. 15.↵
    1. Bakri S. J.,
    2. Ekdawi N. S.

    Intravitreal Silicone Oil Droplets after Intravitreal Drug Injections. Retina 2008, 28 (7), 996–1001.

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    1. Khurana R. N.,
    2. Chang L. K.,
    3. Porco T. C.

    Incidence of Presumed Silicone Oil Droplets in the Vitreous Cavity after Intravitreal Bevacizumab Injection with Insulin Syringes. JAMA Ophthalmol. 2017, 135 (7), 800–803.

    OpenUrl
17. 17.↵
    1. Liu L.,
    2. Ammar D. A.,
    3. Ross L. A.,
    4. Mandava N.,
    5. Kahook M. Y.,
    6. Carpenter J. F.

    Silicone Oil Microdroplets and Protein Aggregates in Repackaged Bevacizumab and Ranibizumab: Effects of Long-Term Storage and Product Mishandling. Invest. Ophthalmol. Vis. Sci. 2011, 52 (2), 1023–1034.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Kocabora M. S.,
    2. Ozbilen K. T.,
    3. Serefoglu K.

    Intravitreal Silicone Oil Droplets following Pegaptanib Injection. Acta Ophthalmol. 2010, 88 (2), e44–e45.

    OpenUrlPubMed
19. 19.↵
    1. Melo G. B.,
    2. Dias Junior C D. S.,
    3. Carvalho M. R.,
    4. Cardoso A. L.,
    5. Morais F. B.,
    6. Figueira A.,
    7. Lima Filho A.,
    8. Emerson G. G.,
    9. Maia M.

    Release of Silicone Oil Droplets from Syringes. Int. J. Retina Vitr. 2019, 5 (1),
20. 20.↵
    1. Olea J. L.,
    2. Gómez-Resa M.,
    3. Cervera-Peris M. M.,
    4. Aragón J. A.

    Silicone Oil Droplets in Repackaged anti–Vascular Endothelial Growth Factors for Intravitreal Injections: In Search of the Main Source of Contamination. Eur. J. Ophthalmol. 2020, 30 (4), 774–779.

    OpenUrlPubMed
21. 21.↵
    1. Schargus M.,
    2. Werner B. P.,
    3. Geerling G.,
    4. Winter G.

    Contamination of anti-VEGF Drugs for Intravitreal Injection: How Do Repackaging and Newly Developed Syringes Affect the Amount of Silicone Oil Droplets and Protein Aggregates?. Retina 2018, 38 (10), 2088–2095.

    OpenUrl
22. 22.↵
    1. Tayyab H.,
    2. Khan A. A.,
    3. Sadiq M. A. A.,
    4. Jahangir S.,
    5. Sarwar S.

    Silicone Oil Droplets in Vitreous after Intravitreal Bevacizumab Injection. Pak. J. Ophthalmol. 2018 35 (2), 144–148.

    OpenUrl
23. 23.↵
    1. Yu J. H.,
    2. Gallemore E.,
    3. Kim J. K.,
    4. Patel R.,
    5. Calderon J.,
    6. Gallemore R. P.

    Silicone Oil Droplets following Intravitreal Bevacizumab Injections. Am. J. Ophthalmol. Case Rep. 2018, 10, 142–144.

    OpenUrlPubMed
24. 24.↵
    1. Scott I. U.,
    2. Oden N. L.,
    3. VanVeldhuisen P. C.,
    4. Ip M. S.,
    5. Blodi B. A.,
    6. Antoszyk A. N.

    SCORE Study Report 7: Incidence of Intravitreal Silicone Oil Droplets Associated with Staked-on vs Luer Cone Syringe Design. Am. J. Ophthalmol. 2009, 148 (5), 725–732.e7.

    OpenUrlCrossRefPubMedWeb of Science
25. 25.↵
    1. Good T. J.,
    2. Kimura A. E.,
    3. Mandava N.,
    4. Kahook M. Y.

    Sustained Elevation of Intraocular Pressure after Intravitreal Injections of anti-VEGF Agents. Br. J. Ophthalmol. 2011, 95 (8), 1111–1114.

    OpenUrlAbstract/FREE Full Text
26. 26.↵
    1. Antoszyk A. N.,
    2. Baker C.,
    3. Calzada J.,
    4. Cummings H.,
    5. So J.,
    6. Quezada-Ruiz C.,
    7. Haskova Z.

    Usability of the Ranibizumab 0.5 mg Prefilled Syringe: Human Factors Studies to Evaluate Critical Task Completion by Healthcare Professionals. PDA J. Pharm. Sci. Technol. 2018, 72 (4), 411–419.

    OpenUrlAbstract/FREE Full Text
27. 27.↵
    1. Souied E.,
    2. Nghiem-Buffet S.,
    3. Leteneux C.,
    4. Bayer S.,
    5. Derveloy A.,
    6. Sagkriotis A.,
    7. Becker G.,
    8. Cohen S.-Y.

    Ranibizumab Prefilled Syringes: Benefits of Reduced Syringe Preparation Times and Less Complex Preparation Procedures. Eur. J. Ophthalmol. 2015, 25 (6), 529–534.

    OpenUrl
28. 28.↵
    1. Subhi Y.,
    2. Kjer B.,
    3. Munch I. C.

    Prefilled Syringes for Intravitreal Injection Reduce Preparation Time. Dan. Med. J. 2016, 63 (4), A5214.

    OpenUrl
29. 29.↵
    1. Michaud J.-E.,
    2. Sigg J.,
    3. Boado L.,
    4. Momm J.,
    5. Weber C.,
    6. Alete D.,
    7. Peregi E.,
    8. Picci M.

    Ranibizumab Pre-Filled Syringe Approved in the European Union: Innovation to Improve Dose Accuracy, Reduce Potential Infection Risk, and Offer More Efficient Treatment Administration. Invest. Ophthalmol. Visual Sci. 2014, 55 (13), 1949.

    OpenUrl
30. 30.↵
    1. Storey P. P.,
    2. Tauqeer Z.,
    3. Yonekawa Y.,
    4. Todorich B.,
    5. Wolfe J. D.,
    6. Shah S. P.,
    7. Shah A. R.,
    8. Koto T.,
    9. Abbey A. M.,
    10. Morizane Y.,
    11. Sharma P.,
    12. Wood E. H.,
    13. Morizane-Hosokawa M.,
    14. Pendri P.,
    15. Pancholy M.,
    16. Harkey S.,
    17. Jeng-Miller K. W.,
    18. Obeid A.,
    19. Borkar D. S.,
    20. Chen E.,
    21. Williams P.,
    22. Okada A. A.,
    23. Inoue M.,
    24. Shiraga F.,
    25. Hirakata A.,
    26. Shah C. P.,
    27. Prenner J.,
    28. Garg S.

    The Impact of Prefilled Syringes on Endophthalmitis following Intravitreal Injection of Ranibizumab. Am. J. Ophthalmol. 2019, 199, 200–208.

    OpenUrl
31. 31.↵
    1. Loewenstein I.,
    2. Goldstein M.,
    3. Moisseiev J.,
    4. Moisseiev E.

    Accuracy and Precision of Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents in Real Life: What is Actually in the Syringe?. Retina 2019, 39 (7), 1385–1391.

    OpenUrl
32. 32.↵
    1. Buerke B.,
    2. Puesken M.,
    3. Mellmann A.,
    4. Seifarth H.,
    5. Heindel W.,
    6. Wessling J.

    Microbiologic Contamination and Time Efficiency of Use of Automatic MDCT Injectors with Prefilled Syringes: Results of a Clinical Investigation. Am. J. Roentgenol. 2010, 194 (2), 299–303.

    OpenUrlCrossRefPubMed
33. 33.↵
    1. Moisseiev E.,
    2. Rudell J.,
    3. Tieu E. V.,
    4. Yiu G.

    Effect of Syringe Design on the Accuracy and Precision of Intravitreal Injections of anti-VEGF Agents. Curr. Eye Res. 2017, 42 (7), 1059–1063.

    OpenUrl
34. 34.↵
    1. Sassalos T. M.,
    2. Paulus Y. M.

    Prefilled Syringes for Intravitreal Drug Delivery. Clin. Ophthalmol. 2019, 13, 701–706.

    OpenUrl
35. 35.↵
    1. Makwana S.,
    2. Basu B.,
    3. Makasana Y.,
    4. Dharamsi A.

    Prefilled Syringes: An Innovation in Parenteral Packaging. Int. J. Pharm. Invest. 2011, 1 (4), 200–206.

    OpenUrl
36. 36.↵
    U.S. Food and Drug Administration, Guidance for Industry and Food and Drug Administration Staff: Applying Human Factors and Usability Engineering to Medical Devices. Center for Devices and Radiological Health: Rockville, MD, 2016.
37. 37.↵
    LUCENTIS (ranibizumab). [package insert]. South San Francisco, CA; Genentech, Inc, 2018.
38. 38.↵
    1. Sukgen E. A.,
    2. Gunay M.,
    3. Kocluk Y.

    Occurrence of Intraocular Air Bubbles during Intravitreal Injections for Retinopathy of Prematurity. Int. Ophthalmol. 2017, 37 (1), 215–219.

    OpenUrl
39. 39.↵
    1. Lim W. S.,
    2. Sikandar M.,
    3. Jackson H.

    Air Entry into the Anterior Chamber Post Intravitreal Injection of Eylea. BMJ Case Reports. 2016, 2016, bcr2016216247.

    OpenUrl
40. 40.↵
    1. Badkar A.,
    2. Wolf A.,
    3. Bohack L.,
    4. Kolhe P.

    Development of Biotechnology Products in Pre-Filled Syringes: Technical Considerations and Approaches. AAPS PharmSciTech 2011, 12 (2), 564–572.

    OpenUrlPubMed
41. 41.↵
    1. Bee J. S.,
    2. Frey V. V.,
    3. Javed U.,
    4. Chung J.,
    5. Corcoran M. L.,
    6. Roussel P. S.,
    7. Krause S. O.,
    8. Cash P. W.,
    9. Bishop S. M.,
    10. Dimitrova M. N.

    Characterization of the Initial Level and Migration of Silicone Oil Lubricant in Empty Prefilled Syringes for Biologics Using Infrared Spectroscopy. PDA J. Pharm. Sci. Technol. 2014, 68 (5), 494–503.

    OpenUrlAbstract/FREE Full Text
42. 42.↵
    1. Funke S.,
    2. Matilainen J.,
    3. Nalenz H.,
    4. Bechtold-Peters K.,
    5. Mahler H.-C.,
    6. Friess W.

    Silicone Migration from Baked-on Silicone Layers. Particle Characterization in Placebo and Protein Solutions. J. Pharm. Sci. 2016, 105 (12), 3520–3531.

    OpenUrl
43. 43.↵
    1. Yoshino K.,
    2. Nakamura K.,
    3. Yamashita A.,
    4. Abe Y.,
    5. Iwasaki K.,
    6. Kanazawa Y.,
    7. Funatsu K.,
    8. Yoshimoto T.,
    9. Suzuki S.

    Functional Evaluation and Characterization of a Newly Developed Silicone Oil-Free Prefillable Syringe System. J. Pharm. Sci. 2014, 103 (5), 1520–1528.

    OpenUrlPubMed
44. 44.↵
    1. Liebmann-Vinson A.

    Physics of Friction Applied to Medical Devices. In: Microstructure and Microtribology of Polymer Surfaces. Vol 741. ACS Symposium Series. American Chemical Society; 1999:474–494. doi:10.1021/bk-2000-0741.ch030.
45. 45.↵
    1. Lanzetta P.,
    2. Holz F.,
    3. Monés J.,
    4. Querques G.,
    5. Stanga P.,
    6. Veritti D.,
    7. Barbone F.,
    8. Brusaferro S.,
    9. Isola M.

    Intravitreal Injections: A Healthcare Failure Modes and Effects Analysis. Ophthalmologica 2013, 230 (3), 151–164.

    OpenUrl
46. 46.↵
    1. Shetty G.,
    2. Zeiss B.

    Microlitre Dosing with Prefillable Syringes—When Does a Device Make Sense? ONdrugDelivery Magazine 2019, (97), 28–31.
47. 47.↵
    1. Krayukhina E.,
    2. Tsumoto K.,
    3. Uchiyama S.,
    4. Fukui K.

    Effects of Syringe Material and Silicone Oil Lubrication on the Stability of Pharmaceutical Proteins. J. Pharm. Sci. 2015, 104 (2), 527–535.

    OpenUrlPubMed
48. 48.↵
    1. Foglia P.,
    2. Prete C. A.,
    3. Zanda M.

    An Inspection System for Pharmaceutical Glass Tubes. WSEAS Transactions on Systems 2015, 14, 123–136.

    OpenUrl